Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS).

TO THE EDITOR: Relapse remains the major cause of failure after allogeneic stem cell transplantation (SCT) and to date, there has been little progress in managing those relapses. Therapeutic options are still limited including supportive care, salvage chemotherapy, donor lymphocyte infusion (DLI), or second SCT. [.]